Antonín Holý


Antonín Holý 1 September 1936 – 16 July 2012 was a pioneering Czech scientist He specialised in the field of chemistry and cooperated on the development of important antiretroviral drugs used in the treatment of HIV and hepatitis B He was involved in the creation of the most effective drug as of early 2009 in the treatment of AIDS1 Antonín Holý is the author of more than 400 scientific discoveries and holds 60 patents2 With more than 400 discoveries to his credit, his work has affected millions of people with viral diseases such as HIV/AIDS and hepatitis B and many other viral diseases3 In 2008 he received an Honorary Professorship at the University of Manchester's School of Chemistry4

Contents

  • 1 Scientific career
  • 2 Death
  • 3 Awards and honours
  • 4 See also
  • 5 Notes
  • 6 External links

Scientific careeredit

Born in Prague, Czechoslovakia, Antonín Holý studied organic chemistry from 1954 to 1959 at the Faculty of Science of Charles University in Prague From 1960 he trained at the Institute of Organic Chemistry and Biochemistry IOCB of the Czechoslovak Academy of Sciences in Prague and has been a researcher there since 1963 He became the Institute's lead scientist in 1967, and from 1983 headed its working group for nucleic acids In 1987 he became chief of the Department of Nucleic Acid Chemistry and from 1994 to 2002 he was head of the IOCB

Since 1976 he has collaborated on the development of new antiretroviral drugs with Erik De Clercq of the Rega Institute for Medical Research at the Catholic University of Leuven, Belgium5

In 2006 the US biopharmaceutical company Gilead Sciences and the Institute of Organic Chemistry and Biochemistry IOCB of the Academy of Sciences of the Czech Republic jointly established a new research center, oriented to the development of new preparations5 Gilead promised the IOCB a $11 million donation, to fund its operations and research for 5 years6

Several antiretroviral drugs based on Holý's discoveries have been licensed In 1996, Vistide was approved for production in the United States and European Union Viread tenofovir was approved in the USA in 2001 for the treatment of AIDS, and Hepsera was approved in 2003 for the treatment of hepatitis B Truvada, a combination of Viread and emtricitabine, was approved in 2006 for use in the USA7

Deathedit

Holý had retired a year before his death and died of an unspecified cause, aged 75, on 16 July 2012 A statement from the IOCB called his death "an immense loss"89 His death occurred two months after the US Food and Drug Administration FDA approved Truvada for treating HIV,3 the same day that FDA approved Truvada for HIV prevention

Awards and honoursedit

  • 1984 State Prize for Chemistry Acyklická analoga nukleosidů a nukleotidů
  • 1998 Hanuš's Medal of the Czech Chemical Society
  • 1999 Honorary doctorate of the Palacký University in Olomouc
  • 2001 Descartes Prize of the European Union;2 The Medal of Merit of the Czech Republic Za zásluhy I degree
  • 2003 Honorary membership in the Rega Institute for Medical Research, Catholic University of Leuven, Belgium
  • 2004 Award Praemium Bohemiae;10 Medal of the Czech Academy of Sciences: De scientia et humanitate optime meritis
  • 2005 Honorary doctorate of the Ghent University Belgium; The Medal of Merit of the Faculty of Science at the Charles University in Prague
  • 2006 Member of the European Academy of Sciences and Arts Salzburg
  • 2006 Honorary doctorate of the Institute of Chemical Technology, Prague
  • 2007 State Prize "Czech Head" Česká hlava

See alsoedit

  • Adefovir
  • Cidofovir
  • Tenofovir

Notesedit

  1. ^ "Faces of the Presidency" EU2009cz Retrieved 8 January 2009 
  2. ^ a b "Czech Chemistry: A Tradition of Innovation and Prosperity" Association for Foreign Investment Retrieved 8 January 2009 
  3. ^ a b "Groundbreaking chemist Antonín Holý dies at 75" Radio Prague 17 July 2012 Retrieved 17 July 2012 
  4. ^ "Antonín Holý received a Honorary Professorship of School of Chemistry" Academic bulletin Retrieved 8 January 2009 
  5. ^ a b "Gilead Sciences and the Institute of Organic Chemistry and Biochemistry IOCB Establish New Academic Research Centre in Prague; Donation by Gilead Honors Leadership of Dr Antonin Holy in Antiviral Drug Discovery and Development" Gilead Retrieved 8 January 2009 
  6. ^ "Gilead Sciences and the Institute of Organic Chemistry and Biochemistry IOCB Establish New Academic Research Centre in Prague" ZoomInfo Retrieved 8 January 2009 
  7. ^ "Truvada tenofovir + emtricitabine" AIDSmedscom Archived from the original on 10 January 2009 Retrieved 8 January 2009 
  8. ^ "Zemřel světoznámý chemik Antonín Holý, objevitel léků pro miliony lidí" Mladá fronta DNES in Czech iDnes 17 July 2012 Retrieved 17 July 2012 
  9. ^ "HIV drug developer Antonin Holy dies" CBCca Retrieved 17 July 2012 
  10. ^ "Praemium Bohemiae podruhé" in Czech Academic Bulletin Retrieved 8 January 2009 

External linksedit

  • Biography, honours, bibliography
  • Antonín Holý at the website of Institute of Organic Chemistry and Biochemistry AS CR, vvi
  • Professor Antonín Holý at wwwczechcz - Personalities of Today
  • Holý's discoveries at the website of 10th International Congress of Dermathology
  • Interview with Antonín Holý about art and science, published in Czech e-daily wwwblistycz, and Slovak daily Obroda, in 2004


Antonín Holý Information about

Antonín Holý

Antonín Holý
Antonín Holý

Antonín Holý Information Video


Antonín Holý viewing the topic.
Antonín Holý what, Antonín Holý who, Antonín Holý explanation

There are excerpts from wikipedia on this article and video



Random Posts

Social Accounts

Facebook Twitter VK
Copyright © 2014. Search Engine